Q1 EPS Estimates for TSE:MDP Cut by Raymond James Financial

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities research analysts at Raymond James Financial dropped their Q1 2027 earnings estimates for shares of Medexus Pharmaceuticals in a report issued on Monday, November 17th. Raymond James Financial analyst M. Freeman now expects that the company will post earnings per share of $0.13 for the quarter, down from their prior estimate of $0.15. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James Financial also issued estimates for Medexus Pharmaceuticals’ Q3 2027 earnings at $0.28 EPS and Q4 2027 earnings at $0.25 EPS.

Separately, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th. Four equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Medexus Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of C$4.57.

Medexus Pharmaceuticals Price Performance

TSE MDP opened at C$2.70 on Wednesday. Medexus Pharmaceuticals has a twelve month low of C$1.96 and a twelve month high of C$5.56. The stock has a market cap of C$87.53 million, a P/E ratio of 135.00 and a beta of 1.21. The company’s 50-day simple moving average is C$2.82 and its 200 day simple moving average is C$2.87.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.